Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update

SA Scott, K Sangkuhl, CM Stein… - Clinical …, 2013‏ - Wiley Online Library
Cytochrome P450 (CYP) 2C19 catalyzes the bioactivation of the antiplatelet prodrug
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …

Cytochrome allelic variants and clopidogrel metabolism in cardiovascular diseases therapy

M Jarrar, S Behl, G Manyam, H Ganah, M Nazir… - Molecular biology …, 2016‏ - Springer
Clopidogrel and aspirin are among the most prescribed dual antiplatelet therapies to treat
the acute coronary syndrome and heart attacks. However, their potential clinical impacts are …

Pharmacogenomics of anti-platelet and anti-coagulation therapy

AS Fisch, CG Perry, SH Stephens… - Current cardiology …, 2013‏ - Springer
Arterial thrombosis is a major component of vascular disease, especially myocardial
infarction (MI) and stroke. Current anti-thrombotic therapies such as warfarin and clopidogrel …

Coding SNPs in hsa-miR-1343-3p and hsa-miR-6783-3p target sites of CYP2C19 modulates clopidogrel response in individuals with cardiovascular diseases

AR Sharma, M Vohra, V Shukla, V Guddattu, AR Uk… - Life sciences, 2020‏ - Elsevier
Aims To investigate the impact of microRNA target SNPs (mirSNPs) and their interaction with
miRNAs on important drug-metabolizing enzymes, transporters and target genes for …

Estimation of plasma levels of warfarin and 7-hydroxy warfarin by high performance liquid chromatography in patients receiving warfarin therapy

DK Kumar, DG Shewade, S Parasuraman… - Journal of Young …, 2013‏ - Elsevier
Warfarin is one of the most commonly prescribed oral anticoagulant for prevention of
thromboembolic events. The effect of this drug is measured by monitoring prothrombin time …

Single nucleotide polymorphism of CYP3A5*3 contributes to clopidogrel resistance in coronary artery disease patients among Tamilian population

R Priyadharsini, DG Shewade, K Subraja… - Molecular biology …, 2014‏ - Springer
Clopidogrel is an antiplatelet drug. It is used for the treatment as well as for the prophylaxis
of coronary artery disease. Clopidogrel resistance is an emerging problem in clinical …

[HTML][HTML] CYP 450 2C19 polymorphisms in Indian patients with coronary artery disease

SS Shetkar, S Ramakrishnan, S Seth, P Chandna… - Indian heart …, 2014‏ - Elsevier
Background Dual antiplatelet therapy is the cornerstone in the management of acute
coronary syndromes (ACS) and prevention of stent thrombosis (ST). Genetic polymorphisms …

Prevalence of clOpidogrel 'resIstaNce'in a selected population of patients undergoing elective percutaneous coronary intervention at a tertiary cardiovascular centre in …

NA Seecheran, A Maharaj, B Boodhai… - Open …, 2019‏ - openheart.bmj.com
Objectives This novel, pilot study aimed to assess the estimated prevalence of high on-
treatment platelet reactivity (HPR) in Trinidad and Tobago. Methods Patients (n= 40) who …

Influence of CYP2C19 loss‐of‐function variants on the metabolism of clopidogrel in patients from north‐western China

R Lin, L Zhang, P Zhang, L Zhou, T Liu… - Journal of clinical …, 2015‏ - Wiley Online Library
What is known and objective Variation of the cytochrome P450 2C19 gene coding for the
CYP 2C19 enzyme has been reported to be associated with clopidogrel response variability …

Implantation and repair of 3D printed myocardial patch in rabbit model of myocardial infarction

X Liu, M Xu, P Li, S Zhao, G Yang, W Zhang, Y Yang - Bioprinting, 2021‏ - Elsevier
In this study, BMSCs were induced to differentiate into cardiomyocytes by 5-azacytidine, and
combined with sodium alginate and gelatin to construct myocardial patch in vitro by 3D bio …